Literature DB >> 229873

Fibrinogen and low density lipoprotein in the development of cerebral atherosclerosis.

S Sadoshima, K Tanaka.   

Abstract

Cerebral arteries from 65 human subjects were examined by immunofluorescence, using antisera against human fibrinogen and low density lipoprotein (LDL). Deposition of fibrinogen and LDL was most frequent at the bifurcation of the middle cerebral arteries and least in the basilar arteries in all age groups. In general, deposition of LDL was associated with deposition of fibrinogen, and lone deposition of LDL in the absence of fibrinogen was only rarely seen. Fibrinogen was scattered in the intercellular spaces, and located in the inner layer or edges of the thickened intima of the bifurcation with increasing plaque formation. Fibrinogen was observed even in the subendothelial region of the uninvolved intima at the bifurcations. LDL was present in the cytoplasm of the endothelial cells in the earliest stage, and it increased in the extracellular stroma with increase in intimal thickening, corresponding closely to the distribution of perifibous oil-red-O-stained lipids. No LDL was detected in the uninvolved intima. The observations suggest that deposition of fibrinogen in the intima might precede LDL deposition and possibly play a more important role than LDL in the development of atherosclerotic lesions in the cerebral arteries, especially in their early stage. Severe atherosclerosis at the bifurcations may be in part due to increased permeation of these plasma proteins, possibly as a result of hemodynamic stress.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 229873     DOI: 10.1016/0021-9150(79)90133-3

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

1.  A prospective study of hyperlipidemia as a pathogenic factor in sudden hearing loss.

Authors:  D Ullrich; G Aurbach; C Drobik
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

2.  Application of HELP in nonarteritic anterior ischemic optic neuropathy: a prospective, randomized, controlled study.

Authors:  A Haas; M Walzl; F Jesenik; B Walzl; A Berghold; J Berglöff; B Feigl; J Faulborn
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-01       Impact factor: 3.117

3.  Monoclonal antibody EMR1a/212D recognizing site of deposition of extracellular lipid in atherosclerosis: purification and characterization of the antigen.

Authors:  K Nakagami; O Shimazaki; R Sato; Y Komine; S Ohkuma; T Takano
Journal:  Am J Pathol       Date:  1989-07       Impact factor: 4.307

4.  Acute phase proteins are major clients for the chaperone action of α₂-macroglobulin in human plasma.

Authors:  Amy R Wyatt; Nathan W Zammit; Mark R Wilson
Journal:  Cell Stress Chaperones       Date:  2012-08-16       Impact factor: 3.667

5.  The rate of re-endothelialization correlates inversely with the degree of the following intimal thickening in vein grafts. Electron microscopic and immunohistochemical studies.

Authors:  Y Shiokawa; M F Rahman; Y Ishii; K Sueishi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

6.  Higher fibrinogen levels predict progression of coronary artery calcification in adults with type 1 diabetes.

Authors:  T C Rodrigues; J K Snell-Bergeon; D M Maahs; G L Kinney; M Rewers
Journal:  Atherosclerosis       Date:  2010-01-04       Impact factor: 5.162

7.  Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes.

Authors:  N Qizilbash; L Jones; C Warlow; J Mann
Journal:  BMJ       Date:  1991-09-14

8.  Permeation and deposition of fibrinogen and low-density lipoprotein in the aorta and cerebral artery of rabbits--immuno-electron microscopic study.

Authors:  T Kurozumi; T Imamura; K Tanaka; Y Yae; S Koga
Journal:  Br J Exp Pathol       Date:  1984-06

9.  Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients.

Authors:  R Fogari; A Zoppi; G D Malamani; G Marasi; A Vanasia; G Villa
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.